YLYong Liu

Yong Liu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yong Liu has a total of 53 co-authors. Here are the top co-authors by number of shared publications:

  • He Bai

    College of Life Sciences, Mudanjiang Medical University, China

    3 shared publications
  • Jiahua Wang

    School of Life Sciences, Mudanjiang Medical University, Tongxiang Street No. 3, Aimin District, Mudanjiang 157011, China

    2 shared publications
  • Muhammad Zohaib Nawaz

    School of Emergency Management, School of the Environment and Safety Engineering, Jiangsu University, Zhenjiang 212013, China

    2 shared publications
  • Syed Zeeshan Haider

    School of Emergency Management, School of the Environment and Safety Engineering, Jiangsu University, Zhenjiang 212013, China

    2 shared publications
  • Yi Lu

    School of Life Sciences, Mudanjiang Medical University, Tongxiang Street No. 3, Aimin District, Mudanjiang 157011, China

    2 shared publications
  • Anqi Lin

    The Key Laboratory for Ultrafine Materials of Ministry of Education , State Key Laboratory of Bioreactor Engineering, Engineering Research Center for Biomedical Materials of Ministry of Education, School of Materials Science and Engineering 130 Meilong Road, Lingyun Street, Xuhui District, Shanghai 200237 , China

    1 shared publication

Latest Publications

  • Open Access

    From Computational Prioritization to Material Supply: A Proposed Two-Axis Record for Marine Invertebrate-Associated Natural Products and Derivatives

    by Yong Liu, Yi Lu, Meiling Su, He Bai, Jiahua Wang, Syed Zeeshan Haider, Muhammad Zohaib Nawaz

    Marine natural products can show biological activity while remaining difficult to identify, reproduce, or obtain in sufficient quantity. This critical narrative review examines that mismatch and proposes a linked record for each exact chemical entity-indication pair. The documented evaluation stage (E1–E4) records computational, in vitro, animal, or human evaluation; the production/access stage (S1–S5) records physical access, an executed laboratory route, controlled pilot production, good manufacturing practice (GMP) clinical manufacture, or established commercial manufacture. Neither coordinate measures therapeutic merit, evidence strength, sustainability, or probability of success. Computational contribution (C), study quality, evidence direction, identity status, regulatory status, and scenario-specific supply adequacy remain separate. Seven purposively selected case lineages illustrate parent-derivative distinctions, computation-linked isolation, untested nominations, later synthesis, and unresolved assay-material identity. Cynthichlorine illustrates incomplete production reporting, while incompletely matched meridianin mixtures remain outside the joint matrix. A calculation comparing reported (+)-aeroplysinin-1 output with an explicitly defined assay requirement makes the supply question concrete without claiming that the scenario was performed. Borderline coding examples and stricter category rules support future independent application. No inter-rater assessment or prospective decision-impact study was performed; the proposal remains unvalidated. Its intended contribution is an auditable connection between evidence, material, and the next proposed experiment, rather than a readiness score.

  • Open Access

    From Computational Prioritization to Sustainable Supply: A Two-Axis Framework for Marine Invertebrate-Associated Natural Products and Derivatives

    by Yong Liu, Yi Lu, Meiling Su, Bai He, Jiahua Wang, Syed Zeeshan Haider, Muhammad Zohaib Nawaz

    Marine invertebrates and their microbial partners provide distinctive chemical scaffolds, but computational prioritization alone can overstate translational progress when experimental support and material supply remain limited. This critical narrative review proposes a linked-record framework for evaluating exact entity-indication pairs on two independent axes: therapeutic-evaluation stage (E1, in silico, to E4, human intervention) and production readiness (S1, discovery access, to S4, GMP or commercial manufacture). E records the highest stage documented in the reviewed sources, not evidence strength or therapeutic success. Computational contribution, evidence direction, study quality, provenance, and scenario-specific supply adequacy remain separate attributes; E and S are not combined into a composite score. Contrasting lineages involving halichondrin B and eribulin, (+)-aeroplysinin-1, a sea-star steroid, acanthomanzamine C, cynthichlorine, gukulenin A, and meridianin mixtures illustrate how uncertain chronology, test-article mismatch, incomplete validation, and poorly characterized production routes affect interpretation. A worked mass balance distinguishes physical access from the amount required for a defined experiment. Supply-by-design therefore integrates identity, route feasibility, demand, ecological constraints, and access obligations at nomination. The framework is preliminary and requires independent reliability and prospective utility testing.

  • Open Access

    Genomic epidemiology, evolution, and transmission dynamics of porcine sapelovirus associated with diarrheic piglets

    by Xia Li, Xin‘ Ao Ma, Xiaoyu Wang, Qingjun Li, Qi Yuan, Jiahua Wang, He Bai, Yong Liu, Feipeng Zhao

    Porcine sapelovirus (PSV) is increasingly detected in swine enteric disease complexes, but its evolutionary dynamics and transmission patterns remain insufficiently characterized. In this study, we analyzed 327 fecal samples collected from diarrheic piglets between 2015 and 2022 and identified persistent PSV detection in northeastern China. Because PSV was detected in the context of mixed enteric viral infections in this dataset, our data do not establish PSV as an independent causative agent of diarrhea. Comparative whole-genome and evolutionary analyses of globally circulating PSV strains revealed substantial genetic diversity, with higher apparent short-term substitution-rate estimates observed in the African and Japanese datasets. In China, inter-strain genetic recombination appeared to represent an additional driver of viral diversification. Temporal evolutionary analyses indicated a dynamic and complex evolutionary landscape within China. Phylogeographic reconstruction identified multiple putative transmission nodes within the currently available genome dataset, suggesting broad geographic dissemination of PSV lineages but not definitive source-sink relationships. These findings enhance our understanding of PSV genomic epidemiology and provide useful information for molecular surveillance of PSV and other diarrhea-associated viruses in swine populations.

  • Open Access

    Nanomedicine-based therapeutic strategies for cerebral ischemia–reperfusion injury: from blood–brain barrier penetration to precision targeting

    by Xiaomeng Guo, Guohao Liu, Yong Liu, Meiling Jin, Zihao Yong, Fukai Li, Shicheng Tang, Liwei Xie, Chunming Huang, Qingchun Mu, et al.

    Cerebral ischemia–reperfusion injury (CIRI) represents a major contributing factor to adverse outcomes following ischemic stroke (IS), posing signifi


  • Open Access

    A putative prognostic model for lung adenocarcinoma based on crotonylation-related genes by bioinformatics and experimental verification

    by Wenting Wang, Baixiang Cui, Haoyue Li, Zihan Zhen, Xueqing Song, Xiaoyu Yuan, Qing Cui, Qi Yuan, Yong Liu

    Backgrounds: Protein crotonylation is a novel post-translational modification implicated in tumorigenesis and progression. Its putative roles and mechanisms in lung adenocarcinoma (LUAD), however, remain incompletely elucidated. Methods: We analyzed the expression of crotonylation-related genes (CRGs) in LUAD samples and identified differentially expressed genes for gene set variation analysis (GSVA). Using GSVA scores as phenotypic traits, weighted gene co-expression network analysis (WGCNA) was applied to identify key module genes. A putative prognostic model was subsequently constructed via Lasso-Cox regression. Functional enrichment, gene mutation analysis, and immune infiltration analyses were conducted to compare high- and low-risk groups. Furthermore, cellular experiments were performed to validate the putative role of the hub gene FAM83A and its regulation of key glycolytic enzymes PKM2 and LDHA. Results: We established a putative crotonylation-related prognostic model for LUAD, which effectively stratified patients into high- and low-risk groups with significantly different overall survival. Functional analysis suggested putative disparities in metabolic pathways between the two groups. Mutation landscape analysis revealed distinct genomic variation patterns, while immune infiltration assessment indicated a putative immune-evasion phenotype in high-risk patients. Cellular assays demonstrated that FAM83A enhances lung cancer cell proliferation, putatively through promoting glycolysis. Our findings establish that FAM83A integrates histone H3K27 crotonylation signaling to drive transcriptional reprogramming of glycolytic metabolism, specifically upregulating key enzymes PKM2 and LDHA. Conclusion: This study proposes a putative prognostic model based on CRGs for LUAD outcome prediction. The hub gene FAM83A may facilitate lung cancer cell growth by regulating glycolysis via PKM2 and LDHA, offering a novel theoretical foundation and a potential target for prognostic assessment and targeted therapy in LUAD patient.


  • Open Access

    Baicalin protects against myocardial fibrosis through inhibition of DOT1L/COL-1 pathway during diabetic cardiomyopathy

    by Qiuling Xu, Zhuoxi Liu, Liyuan Wang, Guoyang Liu, Long Zhao, Hui Yue, Yong Liu

    Diabetic cardiomyopathy (DCM) requires a systematic approach for effective management. Focusing on key signaling pathways in myocardial fibrosis could offer novel therapeutic approaches for DCM. The objective of this research is to investigate new biomarker and the underlying mechanisms by which baicalin intervenes in the progression of DCM. Swiss Target Prediction databases and weighted correlation network analysis (WGCNA) were employed to collect and analyze targets of baicalin and DCM. Intersection targets were obtained through venn online website, network visualization was conducted through STRING database and Cytoscape 3.7.2 software. Molecular docking validation was completed via AutoDock Vina software. Western blotting, RT-qPCR and histology were carried out to validate the direct targets of baicalin and explore the molecular mechanism during DCM progression. In mice induced to DCM, we observed that disruptor of telomeric silencing 1-like (DOT1L) was upregulated. Baicalin (BC) reduced myocardial fibrosis in mice as indicated by the reduced expression levels of fibrosis markers COL-1 and TGF-β. The inhibitory effect of BC was reversed by overexpressed DOT1L and further enhanced by silenced DOT1L. Our results indicate that cardiomyocyte DOT1L exerts a pathogenic role in DCM and BC specifically targets DOT1L/COL-1 signaling to reduce myocardial fibrosis in DCM.


  • Open Access

    Immunomodulatory poly(L-lactic acid) nanofibrous membranes promote diabetic wound healing by inhibiting inflammation, oxidation and bacterial infection

    by Yan Wu, Jin Zhang, Anqi Lin, Tinglin Zhang, Yong Liu, Chunlei Zhang, Yongkui Yin, Ran Guo, Jie Gao, Yulin Li, et al.

    Given the significant impact on human health, it is imperative to develop novel treatment approaches for diabetic wounds, which are prevalent and serious complications of diabetes. The diabetic wound microenvironment has a high level of reactive oxygen species (ROS) and an imbalance between proinflammatory and anti-inflammatory cells/factors, which hamper the healing of chronic wounds. This study aimed to develop poly(L-lactic acid) (PLLA) nanofibrous membranes incorporating curcumin and silver nanoparticles (AgNPs), defined as PLLA/C/Ag, for diabetic wound healing. PLLA/C/Ag were fabricated via an air-jet spinning approach. The membranes underwent preparation and characterization through various techniques including Fourier-transform infrared spectroscopy, measurement of water contact angle, X-ray photoelectron spectroscopy, X-ray diffraction, scanning electron microscopy, assessment of in vitro release of curcumin and Ag+, testing of mechanical strength, flexibility, water absorption and biodegradability. In addition, the antioxidant, antibacterial and anti-inflammatory properties of the membranes were evaluated in vitro, and the ability of the membranes to heal wounds was tested in vivo using diabetic mice. Loose hydrophilic nanofibrous membranes with uniform fibre sizes were prepared through air-jet spinning. The membranes enabled the efficient and sustained release of curcumin. More importantly, antibacterial AgNPs were successfully reduced in situ from AgNO3. The incorporation of AgNPs endowed the membrane with superior antibacterial activity, and the bioactivities of curcumin and the AgNPs gave the membrane efficient ROS scavenging and immunomodulatory effects, which protected cells from oxidative damage and reduced inflammation. Further results from animal studies indicated that the PLLA/C/Ag membranes had the most efficient wound healing properties, which were achieved by stimulating angiogenesis and collagen deposition and inhibiting inflammation. In this research, we successfully fabricated PLLA/C/Ag membranes that possess properties of antioxidants, antibacterial agents and anti-inflammatory agents, which can aid in the process of wound healing. Modulating wound inflammation, these new PLLA/C/Ag membranes serve as a novel dressing to enhance the healing of diabetic wounds.